Agentix Corp. SEC 10-Q Report

Agentix Corp., a clinical-stage biotechnology company specializing in the development of therapeutic agents for metabolic diseases, has released its latest Form 10-Q report. The report highlights the company's financial and operational performance for the three months ended June 30, 2025. The company, which focuses on conditions such as Type 2 diabetes mellitus, obesity, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH), has shown significant changes in its financial metrics and operational activities.

Financial Highlights

• Total Operating Expenses: $200,342, reflecting an increase from $151,305 in the prior year, primarily due to higher research and development costs.
• Loss from Operations: $(200,342), compared to $(151,305) in the previous year, indicating increased operational losses.
• Net (Loss) Income: $(185,824), compared to $(150,717) in the previous year, driven by increased operating expenses and interest expenses.
• Loss per Share - Basic and Diluted: $(0.00), consistent with the prior year, reflecting no change in per-share loss despite increased net loss.

Business Highlights

• Company Overview: Agentix Corp., a clinical-stage biotechnology company, focuses on developing therapeutic agents for metabolic diseases such as Type 2 diabetes mellitus, obesity, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH). The company was incorporated in Nevada and changed its fiscal year end to March 31 in 2022.
• Research and Development: The company increased its research and development expenses to $100,000 for the three months ended June 30, 2025, compared to $55,501 for the same period in 2024. This increase was primarily due to higher R&D consulting costs.
• Professional Fees: Professional fees rose to $82,625 for the three months ended June 30, 2025, from $77,000 in the same period in 2024, mainly due to increased accounting and consulting fees.
• General and Administrative Expenses: There was a slight decrease in general and administrative expenses to $17,717 for the three months ended June 30, 2025, compared to $18,804 for the same period in 2024, primarily due to lower software expenses.
• Foreign Exchange Impact: The company experienced a foreign exchange gain of $15,140 for the three months ended June 30, 2025, compared to a gain of $8,223 in the same period in 2024, due to fluctuations in currency exchange rates.
• Interest Expense: Interest expense increased to $21,226 for the three months ended June 30, 2025, from $7,635 in the same period in 2024, reflecting the company's loan activity.
• Other Income: The company recognized other income of $20,604 for the three months ended June 30, 2025, primarily from a gain on the settlement of accounts payable.
• Future Outlook: The company is attempting to commence operations and generate sufficient revenue. However, its current cash position is insufficient to support daily operations, necessitating further funding through equity or debt financing to continue its business plan and operational activities.

SEC Filing: Agentix Corp. [ AGTX ] - 10-Q - Aug. 22, 2025